1. Predictive and Prognostic Value of sPRR in Patients with Primary Epithelial Ovarian Cancer
    Katrin Kreienbring et al, 2016, Analytical Cellular Pathology CrossRef
  2. Romidepsin alone or in combination with anti-CD20 chimeric antigen receptor expanded natural killer cells targeting Burkitt lymphoma in vitro and in immunodeficient mice
    Yaya Chu et al, 2017, OncoImmunology CrossRef
  3. In vivo effects of dexmedetomidine on immune function and tumor growth in rats with ovarian cancer through inhibiting the p38MAPK/NF-κB signaling pathway
    Qi-Hang Cai et al, 2017, Biomedicine & Pharmacotherapy CrossRef
  4. New insights into antidiabetic drugs: Possible applications in cancer treatment
    Vahid Shafiei-Irannejad et al, 2017, Chem Biol Drug Des CrossRef
  5. Ghrelin accelerates the cartilagic differentiation of rabbit mesenchymal stem cells through the ERK1/2 pathway
    Nan Ye et al, 2017, Cytotechnology CrossRef
  6. Baicalin potentiates TRAIL-induced apoptosis through p38 MAPK activation and intracellular reactive oxygen species production
    Lei Zhang et al, 2017 CrossRef
  7. Reversal of cisplatin resistance by microRNA-139-5p-independent RNF2 downregulation and MAPK inhibition in ovarian cancer
    Ying Chen et al, 2018, American Journal of Physiology-Cell Physiology CrossRef
  8. Pharmacological Inhibition of p38 MAPK by SB203580 Increases Resistance to Carboplatin in A2780cp Cells and Promotes Growth in Primary Ovarian Cancer Cells
    Xiaolu Han et al, 2018, IJMS CrossRef
  9. Overexpression of the lncRNA FER1L4 inhibits paclitaxel tolerance of ovarian cancer cells via the regulation of the MAPK signaling pathway.
    Siwei Liu et al, 2018, J Cell Biochem CrossRef
  10. Growth suppression of human oral cancer cells by candidate agents for cetuximab-side effects.
    Katsuhiro Uzawa et al, 2019, Exp Cell Res CrossRef
  11. InFlo: a novel systems biology framework identifies cAMP-CREB1 axis as a key modulator of platinum resistance in ovarian cancer
    N Dimitrova et al, 2017, Oncogene CrossRef
  12. Two new mixed-ligand coordination polymers based on multi-N chelating ligand inhibit YAP expression and induce caspase-mediated spinal tumor cell apoptosis
    Yi Fu Sun et al, 2019, Braz J Med Biol Res CrossRef
  13. LAMC2 regulated by microRNA-125a-5p accelerates the progression of ovarian cancer via activating p38 MAPK signalling
    Dongya Zhang et al, 2019, Life Sciences CrossRef
  14. Old drug, new trick: Repurposing metformin for gynecologic cancers?
    Terri Febbraro et al, 2014, Gynecologic Oncology CrossRef
  15. Metformin induces degradation of cyclin D1 via AMPK/GSK3β axis in ovarian cancer
    HyeRan Gwak et al, 2017, Mol. Carcinog. CrossRef
  16. Inhibition of CD147 expression promotes chemosensitivity in HNSCC cells by deactivating MAPK/ERK signaling pathway
    Chao Ma et al, 2017, Experimental and Molecular Pathology CrossRef
  17. Overexpression of BMPER in Ovarian Cancer and the Mechanism by which It Promotes Malignant Biological Behavior in Tumor Cells
    Yong Xi et al, 2020, BioMed Research International CrossRef
  18. Hyperglycemia-induced metabolic compensation inhibits metformin sensitivity in ovarian cancer
    Lacey M. Litchfield et al, 2015, Oncotarget CrossRef
  19. CD83, a Novel MAPK Signaling Pathway Interactor, Determines Ovarian Cancer Cell Fate
    Aalia Batool et al, 2020, Cancers CrossRef
  20. Neoadjuvant metformin added to conventional chemotherapy synergizes anti-proliferative effects in ovarian cancer
    Kuo-Chang Wen et al, 2020, J Ovarian Res CrossRef
  21. Recycling the Purpose of Old Drugs to Treat Ovarian Cancer.
    Mariana Nunes et al, 2020, Int J Mol Sci CrossRef
  22. Metformin Suppresses Tumor Progression by Inactivating Stromal Fibroblasts in Ovarian Cancer
    Sen Xu et al, 2018, Mol Cancer Ther CrossRef
  23. Metformin and survival: Is there benefit in a cohort limited to diabetic women with endometrial, breast, or ovarian cancer?
    Lara S. Lemon et al, 2022, Gynecologic Oncology CrossRef
  24. The Chemosensitizing Role of Metformin in Anti-Cancer Therapy
    Zhimin Tang et al, 2021, ACAMC CrossRef
  25. Sera from women with different metabolic and menopause states differentially regulate cell viability and Akt activation in a breast cancer in-vitro model
    Laura C. Flores-García et al, 2022, PLoS ONE CrossRef
  26. Role of p38 MAP kinase in cancer stem cells and metastasis
    Sriya Kudaravalli et al, 2022, Oncogene CrossRef
  27. Pitavastatin and Ivermectin Enhance the Efficacy of Paclitaxel in Chemoresistant High-Grade Serous Carcinoma
    Mariana Nunes et al, 2022, Cancers CrossRef
  28. Targeting the (pro)renin receptor in cancers: from signaling to pathophysiological effects
    Xin Ouyang et al, 2022, J Cancer Res Clin Oncol CrossRef
  29. MAPK Signaling Pathway in Oral Squamous Cell Carcinoma: Biological Function and Targeted Therapy
    Yuxi Cheng et al, 2022, Cancers CrossRef
  30. Metformin Improves Ovarian Cancer Sensitivity to Paclitaxel and Platinum-Based Drugs: A Review of In Vitro Findings
    Giovanni Tossetta, 2022, IJMS CrossRef
  31. The Antineoplastic Effect of Carboplatin Is Potentiated by Combination with Pitavastatin or Metformin in a Chemoresistant High-Grade Serous Carcinoma Cell Line
    Mariana Nunes et al, 2022, IJMS CrossRef
  32. In Vitro Anticancer Activity of Novel Ciprofloxacin Mannich Base in Lung Adenocarcinoma and High-Grade Serous Ovarian Cancer Cell Lines via Attenuating MAPK Signaling Pathway
    Michael A. Fawzy et al, 2023, Molecules CrossRef
  33. The Potential Therapeutic Impact of Metformin in Glioblastoma Multiforme
    Mehdi Sanati et al, 2023, CMC CrossRef
  34. Talcum powder induces malignant transformation in normal human primary ovarian epithelial cells
    Amy K. HARPER et al, 2023, Minerva Obstet Gynecol CrossRef
  35. Research progress on traditional Chinese medicine-induced apoptosis signaling pathways in ovarian cancer cells
    Yu Wang et al, 2024, Journal of Ethnopharmacology CrossRef
  36. Enhancing Immunotherapy in Ovarian Cancer: The Emerging Role of Metformin and Statins
    Diana Luísa Almeida-Nunes et al, 2023, IJMS CrossRef
  37. Drug Repositioning for Ovarian Cancer Treatment: An Update
    Maria Maddalena Cavalluzzi et al, 2024, ACAMC CrossRef